Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: An indirect treatment comparison meta-analysis
Adalimumab Significantly Reduces the Recurrence Rate of Anterior Uveitis in Patients with Ankylosing Spondylitis
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)
Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
Adalimumab for Pediatric Sympathetic Ophthalmia
Adalimumab and Infliximab Are Equally Effective for Crohn%26apos;s Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor-alpha Agents
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis
Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials
Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease
Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis
Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina
Adalimumab in der Behandlung des adulten Morbus Crohn - Updateeines Konsensus der Arbeitsgruppe Chronisch EntzundlicheDarmerkrankungen der osterreichischen Gesellschaftfur Gastroenterologie und Hepatologie
Adalimumab in anti-synthetase syndrome
Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn%26apos;s Disease: A Randomized Controlled Trial
Adalimumab-induced lupus panniculitis
Adalimumab for the Treatment of Ulcerative Colitis - A Consensus Report by the Working Group Inflammatory Bowel Diseases of the Austrian Society of Gastroenterology and Hepatology
Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre
Adalimumab in the treatment of rheumatoid arthritis
Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis
Adaline对权扰动敏感性的近似计算
Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials
Adalimumab in pediatric Crohn's disease
Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption
Adalimumab Therapy in Children With Crohn Disease Previously Treated With Infliximab
Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis
Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double- blind, placebo-controlled trial
Adalimumab for the Treatment of Japanese Patients With Intestinal Behcet's Disease
Adalimumab arrests bone loss in the spine and hip of active rheumatoid arthritis patients with osteopenia
Adalimumab-Induced Cutaneous Lupus Erythematosus in a 16-Year-Old Girl with Juvenile Idiopathic Arthritis
Adalimumab markedly improves enthesitis in patients with psoriatic arthritis: Evaluation with a magnetic resonance imaging scoring system
Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study
Adalimumab Treatment for SAPHO Syndrome
Adalimumab treatment for life threatening pulmonary artery aneurysm in Behcet disease: a case report
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease
Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection
Adalimumab-Induced Psoriasis of the Scalp with Diffuse Alopecia: A Severe Potentially Irreversible Cutaneous Side Effect of TNF-Alpha Blockers
Adalimumab Level in Breast Milk of a Nursing Mother
Adalimumab Treatment in Children with Refractory Crohn's Disease
Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre
Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement
Adalimumab in Patients with Active Noninfectious Uveitis
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial
Adalimumab ameliorates OVA-induced airway inflammation in mice: Role of CD4(+) CD25(+) FOXP3(+) regulatory T-cells
Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease
Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-alpha on tight junction proteins and signaling pathways in intestinal epithelial cells
Adalimumab-induced lupus erythematosus
Adalimumab or Cyclosporine as Monotherapy and in Combination in Severe Psoriatic Arthritis: Results from a Prospective 12-month Nonrandomized Unblinded Clinical Trial
Adalimumab Induces Deep Remission in Patients With Crohn's Disease
Adalimumab for the treatment of inflammatory bowel disease
Adalimumab Ameliorates Abdominal Aorta Cross Clamping Which Induced Liver Injury in Rats
Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update
Adalimumab (antitumour necrosis factor-alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study
Adalimumab: A Review of Its Use in the Treatment of Patients with Ulcerative Colitis
Adalimumab in dermatology
Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study
Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis
Adalimumab for treatment of severe Behcet's uveitis: a retrospective long-term follow-up study
Adalimumab Plus Narrowband Ultraviolet B Light Phototherapy for the Treatment of Moderate to Severe Psoriasis
Adalimumab in Crohn's Disease: Tips and Tricks After 5 Years of Clinical Experience
Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(-) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a nonrandomized pilot intervention study
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Adalimumab reversed a severe lymphopenia in a patient with Crohn's disease
Adalimumab in budesonide and methotrexate refractory collagenous colitis
Adalimumab Dose Tapering in Psoriasis: Predictive Factors for Maintenance of Complete Clearance
Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
Adalimumab for the treatment of uveitis
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept
Adalimumab effectiveness in Beh double dagger et's disease: short and long-term data from a multicenter retrospective observational study
Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target
Adalimumab-induced remission of anterior scleritis: a very rare late manifestation of Takayasu arteritis
Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs
Adalimumab-induced lupus pernio-like eruption in a patient with psoriasis
Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice
Adalimumab-induced porokeratosis
Adalimumab for Ocular Inflammation
Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal